Our Work

We are inspired by companies, researchers and entrepreneurs who want to make a true difference We work with great clients and great people. Catalyze supports a variety of Life Sciences developments including, but not limited to, diagnostics, pharmaceuticals, medical devices and healthcare solutions. Our clients range from researchers at academic hospitals and universities, to non-profit organizations, start-ups,… Continue Reading

Revolutionary antibiotics test

Revolutionary antibiotics test

Resistance to antibiotic treatments is becoming a worldwide medical and economic problem. Because an Antimicrobial Susceptibility Tests (AST) takes over 48 hours, physicians are often required to start an empiric large spectrum therapy. But a solution is just around the corner.

Unique and innovative material for better cranioplasty results

Unique and innovative material for better cranioplasty results

Cranioplasty is the surgical intervention to repair cranial defects. Reconstructions with the patient’s own bone flap are preferred because of its cosmetic results, lower cost, and bio integration.

€ 1.9 million for new diagnostic Lyme test

€ 1.9 million for new diagnostic Lyme test

The ID-LYME project that will bring a novel Lyme Borreliosis test to the market, was awarded a 1.9 million grant by the Horizon 2020 Fast Track to Innovation scheme.

MedEye

MedEye

The large diversity in medication and the growing amounts, require a delicate and precise distribution process.

Grant for Rare disease research

Grant for Rare disease research

For a rare condition like CPVT, an inherited cardiac arrhythmia syndrome with a prevalence of 1 in 10,000 that causes sudden cardiac death, therapies are not always accessible. Catalyze wrote a proposal for a consortium led by the Academisch Medisch Centrum in Amsterdam, resulting in an ERA-Net E-Rare grant.

Grant for research rare mitochondrial disease

Grant for research rare mitochondrial disease

A ZonMW PM-RARE grant of € 3.0 million was awarded to a national consortium consisting of the RUNMC, Khondrion BV (Nijmegen), Mercachem BV (Nijmegen) and three mitochondrial patient organizations (VSN, ESN and IMP). Catalyze was responsible for writing the proposal.